We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
+9.75%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
-$1.28M
Cap. Flow
-$11.4M
Cap. Flow %
-8.5%
Top 10 Hldgs %
21.49%
Holding
245
New
28
Increased
29
Reduced
140
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$2.85M
2
ATEC icon
Alphatec Holdings
ATEC
+$2.84M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$2.84M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$2.12M
5
APLS
Apellis Pharmaceuticals
APLS
+$1.76M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.17M
2
PCRX icon
Pacira BioSciences
PCRX
+$3.36M
3
PFE icon
Pfizer
PFE
+$3.06M
4
UTHR icon
United Therapeutics
UTHR
+$2.79M
5
QURE icon
uniQure
QURE
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 57.92%
2 Real Estate 14.45%
3 Financials 7.05%
4 Industrials 3.2%
5 Technology 2.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZS icon
226
Zscaler
ZS
$24.2B
$25.3K 0.02%
148
-4
-3% -$731
SMCI icon
227
Super Micro Computer
SMCI
$15.6B
$20.4K 0.02%
490
-20
-4% -$1.22K
SNOW icon
228
Snowflake
SNOW
$93.2B
$18.8K 0.01%
164
-5
-3% -$615
AUPH icon
229
Aurinia Pharmaceuticals
AUPH
$2.05B
– –
-80,000
Closed -$457K
BCRX icon
230
BioCryst Pharmaceuticals
BCRX
$2.36B
– –
-675,000
Closed -$4.17M
CABA icon
231
Cabaletta Bio
CABA
$461M
– –
-70,000
Closed -$524K
DCGO icon
232
DocGo
DCGO
$64.3M
– –
-650,000
Closed -$2.01M
IWD icon
233
iShares Russell 1000 Value ETF
IWD
$81.9B
– –
-2,762
Closed -$482K
KALV
234
DELISTED
KalVista Pharmaceuticals
KALV
– –
-2,500
Closed -$29.4K
PCRX icon
235
Pacira BioSciences
PCRX
$1.01B
– –
-117,500
Closed -$3.36M
QURE icon
236
uniQure
QURE
$2.77B
– –
-460,000
Closed -$2.06M
RPV icon
237
Invesco S&P 500 Pure Value ETF
RPV
$1.58B
– –
-5,715
Closed -$477K
TUR icon
238
iShares MSCI Turkey ETF
TUR
$204M
– –
-2,894
Closed -$122K
VTYX
239
DELISTED
Ventyx Biosciences
VTYX
– –
-10,000
Closed -$23.1K
NARI
240
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-15,000
Closed -$722K
CERE
241
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-42,500
Closed -$1.74M
6 7 8 9
10

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, AlphaCentric Advisors held 245 positions worth $135M, down 0.95% from $136M the previous quarter. Its ten largest holdings account for 21% of the portfolio.

AlphaCentric Advisors withdrew a net $11.4M in Q3 2024, closing 15 positions and reducing 140 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $4.17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 60% a quarter earlier, followed by Real Estate and Financials.

Against the trend, AlphaCentric Advisors opened a new position in Merck worth $2.73M.

  • AlphaCentric Advisors's largest Q3 2024 buy was Merck: 24,000 shares worth $2.73M.
  • AlphaCentric Advisors added most to Neurocrine Biosciences in Q3 2024, an estimated $2.12M increase.
  • AlphaCentric Advisors's biggest Q3 2024 reduction was Pfizer, cutting an estimated $3.06M.
  • AlphaCentric Advisors fully exited BioCryst Pharmaceuticals in Q3 2024, selling an estimated $4.17M.
  • AlphaCentric Advisors's ten largest holdings make up 21% of its $135M portfolio in Q3 2024.
  • AlphaCentric Advisors opened 28 new positions and closed 15 in Q3 2024.
  • AlphaCentric Advisors's portfolio value fell 0.95% quarter-over-quarter to $135M.

Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.